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Abstract 
            Water soluble vitamins like Vitamin B3, B6 and B9 are of utmost importance 
in human health and disease, as they are involved in numerous critical metabolic 
reactions. Not surprisingly, deficiencies of these vitamins have been linked to various 
disease states. For examples, Vitamin B6 deficiency has been related to many diseases 
in humans especially in women with type 1 diabetes and in patients with systemic 
inflammation, liver disease, rheumatoid arthritis, and those infected with HIV. 
Similarly, derivatives of Vitamin B9 (such as folates), are needed to synthesize, repair, 
and methylate DNA as well as to act as a cofactor in certain biological reactions. The 
aim of this study was to develop a sensitive and robust HPLC/LC-MS/MS method for 
the determination of blood levels of vitamins B6 and B3 from human plasma and to 
apply it for the quantification of these vitamins in healthy and obese Emirati population 
in the Al Ain region of UAE. 
Keywords: Vitamins, obesity, Emirati population, bioanalytical quantification, serum. 
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Title and Abstract (in Arabic) 
ألشخاص أصحاء و بدناء في  6وب 3التحليل الكروماتوجرافي لفيتامين ب
ماراتي بمدينه العين إلالمجتمع ا  
 الملخص
تعتبر من الفيتامينات  9وفيتامين ب 6، فيتامين ب 3الفتامينات الذائبه في الماء مثل فيتامين ب
والوقايه من بعض األمراض، ألنهم يدخلون في كثير من العمليات الحيويه نسان إلالمهمه لصحه ا
الذي  6نسان لذلك نقصهم أصبح مرتبط  بأمراض كثيره، ومثال علي ذلك فيتامين بإلفي جسم ا
لتهابات الروماتيزميه، ومرض رتبط نقصه بالسكري نوع أول في النساء، وأمراض الكبد، واإلإ
 لتهابات المزمنه.ر من اإليدز( وكثيإلنقص المناعه )ا
صالح الحمض النووي إرتبط بأهميته في تخليق وإالذي  9ي ذلك أيضا فيتامين بلو من األمثله ع
 عامل مساعد في العمليات الحيويه بالجسم لذلك نقصه يؤدي لخلل فيها.أيضا يعتبرو
)الفصل جهازإستخدام و في هذه الدراسه كان هدفنا هوعمل طريقه تحليليه دقيقه وفعاله ب
في عينات دم خاصه بمجموعه من  6ب و 3بالكروماتوجرافي( يمكننا بها قياس مستوي فيتامين 
 مارات العربيهإلماراتي في مدينه العين بدوله اإلأشخاص بدناء وأشخاص أصحاء من المجتمع ا
 ة.المتحد
 
 ما الدمبالز ،تحليل بيولوجى ،ماراتإلسكان ا ،البدانة ،: الفيتاميناتمفاهيم البحث الرئيسية
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Chapter 1: Introduction 
1.1 Historical background  
Vitamins are a group of compounds that serve as co-factors for numerous 
metabolic reactions functions in the cell. They form a cohesive group of organic 
compounds that are required in human diet in small amounts (micrograms or 
milligrams per day) to maintain various chemical and physiological functions in the 
body [1]. Therefore, vitamins are distinguished from the essential inorganic minerals, 
amino acids, and fatty acids, which are required in larger amounts [1]. Vitamins were 
discovered at the beginning of the twentieth century by Hopkins [2], when he noticed 
that a small amount of milk added to the diet of rats helped them in their growth as 
compared with fats, proteins and carbohydrates. He concluded that one or more 
essential growth factors are present in milk in small amounts, but were adequate to 
maintain growth and development of the rats [2]. The first of these essential growth 
factors was discovered in 1912 and was found to be amine in nature. Due to the fact 
that it was realized as being important to life, it was called “vita amine”, or vitamin, 
where vita means life in the Latin language, while amine was believed to be related to 
ammonia in the Latin language [3]. Although next discovered essential growth factors 
were not amines in nature, they are still grouped as vitamins.  
Similar to most chemical compounds, vitamins are named after their chemical 
structures. In addition, vitamins are also given names arising from the history of their 
discovery. For several vitamins, a number of chemically related compounds show 
similar biological activity, because they are either converted to the same final active 
metabolite or have sufficient structural similarity to have the same activity. These are 
collectively known as vitamers [4].   
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For a compound to be considered a vitamin, it must be shown to be an essential 
part of a   regular diet, and that its deficiency must result in a clearly defined disease, 
while restoration must cure or prevent that deficiency which causes a disease. In 
addition, demonstrating that a compound has pharmacological actions, and possibly 
cures a disease, does not classify that compound as a vitamin, even if it is a naturally 
occurring compound that is found in foods. Moreover, demonstrating that a compound 
has a physiological function as a coenzyme or hormone does not classify that 
compound as a vitamin, and it is necessary to demonstrate that endogenous synthesis 
of a vitamin is inadequate to meet the physiological requirements of the body, in the 
absence of a dietary source of that compound.  
 
1.2 Classification of vitamins 
Vitamins are often classified based on their solubility into fat- or lipid-soluble 
and water-soluble vitamins [1]. While the former includes vitamins A, D, E, and K. 
The latter is composed of vitamin C and eight B-vitamins, namely thiamine (vitamin 
B1), riboflavin (vitamin B2), niacin (vitamin B3), pyridoxine (vitamin B6), 
pantothenic acid (vitamin B5), biotin (vitamin B7), folate (vitamin B9) and 
cyanocobalamin (vitamin B12). Vitamin solubility factor, does not only decide their 
distribution in various food groups, but it also plays an important part in their analysis 
and quantification. Tables 1 and 2 show a list of fat- and water-soluble vitamins, their 
common names, their chemical structures and their food sources [1]. The distinction 
between fat- and water-soluble vitamins is solely based on the difference in chemical 
structure of the vitamins, where fat-soluble vitamins are mainly hydrophobic or 
lyophilic in nature. Water-soluble vitamins are hydrophilic in nature by virtue of the 
polar groups, such as –OH, -NH2, and –COOH. Despite this classification, it should 
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be noted that water-soluble derivatives of vitamins A, K, vitamin B fat-soluble 
derivatives and vitamin C have been developed for therapeutic use and also as food 
additives. Fat-soluble vitamins dissolve in fat before they are absorbed in the blood 
stream to carry out their functions. Excessive amount of these vitamins are often stored 
in the liver; as they are not needed every day in the diet. In contrast, water-soluble 
vitamins dissolve in water and are not stored as they are often eliminated in urine. 
Therefore, a continuous supply of these vitamins is needed in our daily diet.  
 
1.3  Vitamins and food sources 
Regular foods are often enriched with vitamins in stated amounts during their 
processing. However, frequently manufacturers commonly add more than the stated 
amount, which may cause health problems in certain cases. For example, recently a 
debate arose in USA concerning folate enrichment of flour, because of the small 
difference between the amount that is considered desirable and the amount that may 
be hazardous, and the precision to which manufacturers can control the amount in the 
final products [5]. Interestingly, the U.S. Pharmacopeia permits pharmaceutical 
preparations to contain from 90% to 150% of the declared amount of water-soluble 
vitamins and from 90% to 165% of the fat-soluble vitamins [1]. 
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Table 1: Names, chemical structure and sources of fat-soluble vitamins [6] 
Name Common name Structure Sources 
Vitamin A Retinol 
 
Broccoli, Carrot, 
Spinach, Apricot, 
Tomatoes, Milk, 
pumpkin 
Vitamin D Choleocalciferol 
(Vitamin D3) 
 
 
Egg yolk, Salmon, Tuna, 
Sunflower seeds, Milk, 
Sun 
Vitamin E -tocopherol 
 
Wheat germ  oil, 
Almond, Kiwi, Broccoli, 
Mango , Avocados 
Vitamin K Phylloquinone 
(Vitamin K1) 
 
Spinach, Lettuce, 
Avocado, Asparagus, 
Parsley  
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Table 2: Names, chemical structure and sources of water-soluble vitamins [7] 
Name Common name Structure Sources 
Vitamin C Ascorbic acid 
 
Red pepper, Kiwi, 
Broccoli, Spinach, 
Grapefruit, Avocado, 
orange, Banana 
Vitamin B1 Thiamine 
 
Legumes, Rice, Corn 
flour, Spinach 
Vitamin B2 Riboflavin 
 
Milk, 
Cheese, Eggs, leafy 
vegetables, liver, 
Mushrooms, Almond 
Vitamin B3 Niacin 
 
Sesame seed, Ginger, 
Green sweet pepper, 
baked Potato 
Vitamin B5 Pantothenic 
acid 
 
Dried Mushrooms, 
Liver, dried Egg yolks, 
Sunflower seeds  
Vitamin B6 Pyridoxine 
 
Banana, Watermelons, 
brown Rice, Salmon, 
Tuna, Chicken 
Vitamin B7 Biotin 
 
Egg, Pecans, Penuts, 
Green peas, Butter 
Vitamin B9 Folic acid 
 
Leafy vegetables, 
Avocado, Beetroot, 
Spinach, Liver, Yeast 
Vitamin B12 Cobalamin 
 
Clams, Lamb liver, Fish 
eggs, Crab meat 
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It should be mentioned that concentrations of vitamins in the body are strongly 
linked to their intake in the daily regular meals. Most of the vitamins are absorbed by 
active transport, therefore, the percentage that is absorbed will decrease as the intake 
increases. Fat-soluble vitamins (A, D, E, and K) are absorbed in lipid micelles, and, 
therefore, absorption will be impaired when the meal is low in fat. Gastrointestinal 
pathology that results in impaired fat absorption will also impair the absorption of fat-
soluble vitamins, because they remain dissolved in the unabsorbed lipid in the 
intestinal lumen [8]. Lipase inhibitors used for the treatment of obesity and fat 
replacers (e.g., sucrose polyesters such as OlestraTM) will similarly impair the 
absorption of fat-soluble vitamins. On the other hand, many of the water-soluble 
vitamins are present in foods bound to proteins, and their release may require either 
the action of gastric acid (as for vitamin B12) or specific enzymatic hydrolysis [e.g., 
the action of conjugase to hydrolyze folate conjugates and the hydrolysis of biocytin 
to release biotin. In addition to the above, the state of body reserves of the vitamin may 
affect the extent to which it is absorbed (by affecting the synthesis of binding and 
transport proteins) or the extent to which it is metabolized after uptake into the 
intestinal mucosa. There are also compounds naturally present in foods that may have 
antivitamin activity [8]. For example, certain foods contain thiaminases and 
compounds that catalyze nonenzymic cleavage of thiamine to biologically inactive 
products. Moreover, drugs and compounds that are naturally present in foods may 
compete with vitamins for absorption. For example, chlorpromazine, tricyclic 
antidepressants, and a number of antimalarial drugs inhibit the intestinal transport and 
metabolism of riboflavin; carotenoids lacking vitamin A activity compete with β-
carotene for intestinal absorption and metabolism; and alcohol inhibits the active 
transport of thiamine across the intestinal mucosa [8]. 
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A number of vitamins are present in foods in chemical forms that are not 
readily available for absorption in the body. For example, much of the vitamin B6 in 
plant foods is present as pyridoxine glycosides, which are only partially bioavailable, 
and may also antagonize the metabolism of free pyridoxine [9]; excessive heating can 
lead to nonenzymic formation of pyridoxyllysine in foods, rendering both the vitamin 
and the lysine unavailable. Similarly, most of the niacin in cereals is present as niacytin 
(nicotinoyl-glucose esters in oligosaccharides and non-starch polysaccharides), which 
is only hydrolyzed to a limited extent by gastric acid. Moreover, protein binding of a 
vitamin on foods increases its absorption and hence its biological availability. For 
example, folate from milk is considerably better absorbed than that from either mixed 
food folates or free folic acid. Folate bound to a specific binding protein in milk is 
absorbed in the ileum, whereas free folate monoglutamate is absorbed in the (smaller) 
jejunum. 
 
1.4 Water-soluble vitamins 
Water-soluble vitamins readily dissolve in water and are not stored as they are 
eliminated in urine. Therefore, a continuous supply of them is needed in our diets. The 
water-soluble vitamins can be divided into the B-complex group and vitamin C. Water-
soluble vitamins are easily destroyed or washed out during food storage or preparation. 
However, proper storage and preparation can minimize their loss. Eight different 
water-soluble vitamins make up the B-complex group: thiamine (vitamin B1), 
riboflavin (vitamin B2), niacin, vitamin B6, folate, vitamin B12, biotin and pantothenic 
acid. These vitamins are widely distributed in foods. Their influence is felt in many 
parts of the body. They function as coenzymes that help the body obtain energy from 
food. They also are important for normal appetite, good vision, healthy skin, healthy 
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nervous system and red blood cell formation. Beriberi, pellagra and pernicious anemia 
are three well-known B-vitamin deficiencies [10]. These diseases are not a problem in 
the United States, but occasionally they occur when people omit certain foods or 
overeat certain foods at the expense of others. Alcoholics are especially prone to 
thiamin deficiency because alcohol replaces food. Vegans will need a B12 supplement. 
When grains and grain products are refined, essential nutrients lost during 
processing are put back into these foods through a process called enrichment. Among 
the nutrients added during the enrichment process are thiamin, niacin, riboflavin, folate 
and iron. Some examples of enriched grain products are white rice, many breakfast 
cereals, white flour, breads and pasta. For some populations, rice is the main dietary 
staple. When “polishing” rice (removing its outer layers) became popular, thiamin 
deficiency, or beriberi, increased significantly [10]. 
In the early 1900s, the most widespread vitamin deficiency disease in the 
United States was pellagra, or niacin deficiency. At that time, pellagra caused 
thousands of deaths and many cases of mental and physical illness among the poor in 
the Southeast. The enrichment of flour, rice and wheat products helped to eliminate 
the deficiency problems found in people who depended on these food items for most 
of their daily calories. Table 3 shows the source, major functions, deficiency 
symptoms, the over consumption symptoms and the stability in foods of water-soluble 
vitamins [11].  
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Table 3: Water-soluble vitamins and their characteristics [11] 
Vitamins Best sources Function Deficiency 
Symptoms 
Daily 
Amount 
B-1  
(Thiamin) 
Whole wheat 
products, pork, 
liver, and peas 
Helps convert 
carbohydrates to 
energy 
Loss of energy, 
nerve damage, 
muscle weakness 
12.5 mg, 
2x daily 
B-2  
(Riboflavin) 
Meats, fish, 
whole grains, 
dairy products, 
vegetables, 
legumes 
Aids many enzyme 
reactions that 
convert food into 
energy 
Dry, scaly skin, 
cracks on lips and 
corners of mouth, 
light sensitivity 
12.5 mg, 
2x daily 
Niacin Whole grains, 
dairy products, 
liver 
Aids many enzyme 
reactions that 
convert food into 
energy 
Mental impairment, 
delirium, diarrhea, 
swelling of mouth 
15 mg,  
2x daily 
B-6 Meats, fish, nuts, 
whole grains, 
fruits, 
vegetables, 
legumes 
Helps convert 
protein’s amino 
acids into energy, 
Synthesizes: amino 
acids, muscle 
proteins, 
hemoglobin, insulin, 
and immune proteins 
Depression, loss of 
energy, loss of 
appetite, nausea, 
vomiting, swelling 
of mouth and tongue 
2 mg,  
2x daily 
Folate  
(also known 
as: F, B9, 
Folic Acid, 
or Folacin) 
Liver, kidney, 
dark green leafy 
vegetables, 
fruits, peas, and 
beans 
Required for DNA 
metabolism, 
important for genetic 
functions such as 
cell division and 
growth 
Anemia, swelling of 
tongue, diarrhea. In 
pregnancy, anemia, 
miscarriage, and 
birth defects 
200 mcg, 
2x daily 
B-12 Liver, kidney, 
red meats, dairy 
products, eggs, 
fish 
Required for DNA 
metabolism, red 
blood cell formation, 
maintains central 
nervous system 
Anemia, 
degenerative 
changes in the 
nervous system 
400 mcg, 
2x daily 
Pantothenic 
Acid 
Liver, kidney, 
yeast, egg yolks, 
peanuts, whole 
grains, beef, 
skim milk, 
potato, tomato 
Helps convert fatty 
acids into energy. 
Synthesis of fatty 
acids, cholesterol, 
hormones 
No appetite, nausea, 
indigestion, moods, 
cramps, depressed 
immune system, 
rapid pulse, fainting 
150 mg, 
2x daily 
Biotin Liver, kidney, 
egg yolks, milk, 
yeast 
Helps digest 
carbohydrates and 
make fatty acids 
No appetite, anemia, 
scaly skin, weight 
loss, hair loss 
150 mcg, 
2x daily 
C  
(Ascorbic 
Acid) 
Fruits (especially 
citrus) and 
vegetables 
Aids in wound 
healing, improves 
immune system, 
helps make amino 
acids, helps iron 
absorption 
Anemia, depressed 
immune system, 
bruising, weakened 
bones and cartilage, 
muscle degeneration 
250 mg, 
2x daily 
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Vitamin B referred to a vitamin whose deficiency causes beriberi in man and 
polyneuritis in birds. Later, Goldberger’s researches on pellagra led to the view that 
vitamin B consisted of at least 2 factors: a heat-labile antiberiberi factor and a 
comparatively heat-stable antipellagra factor. Some called the former factor as 
vitamin B1 and the latter as vitamin B2. But the later researches conducted by Richard 
Kuhn, Conrad Elvehjem and others have established the fact that vitamin B complex, 
as represented by yeast, rice bran and liver extracts, contains still other factors. At 
present, the vitamin B complex is known to consist of a group of at least 13 
components usually named as B1, B2, B3 etc. But to prevent confusion, their chemical 
names are now frequently used [12]. The various members of the vitamin B complex 
are not related either chemically or physiologically, yet they have many features in 
common: 
(a) All of them are water-soluble. 
(b) Most of them, if not all, are components of coenzymes that play vital roles 
in metabolism (Table 4). Table 5 demonstrates the coenzyme reactions that B 
vitamins are involved in.  
(c) Most of these can be obtained from the same source, i.e., liver and yeast. 
(d) Most of them can be synthesized by the intestinal bacteria. 
Several water soluble vitamin metabolites are involved in cellular metabolism, 
mainly as coenzymes, to prevent metabolic disorders. Most of them are essential for 
energy metabolism. The phosphorylated forms of thiamine (Vit.B1) play a key role in 
the Krebs cycle [13,14]. Riboflavin (Vit.B2), niacin (Vit.B3), pantothenic acid 
(Vit.B5), pyridoxal 5-phosphate (circulating form of Vit.B6), 5-methyl 
tetrahydrofolate (circulating form of Vit.B9) and biotin (Vit.B8) are involved in 
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oxidation/reduction reactions, fatty acid and neurotransmitters synthesis or one carbon 
metabolism [15-18].  
Because all these vitamers are directly involved in various body functions, their 
deficiency will impact human health. Supplementation is therefore highly 
recommended for targeted populations such as pregnant women, lactating women, 
infants, elderly and athletes to either prevent diseases and/or risks such as 
cardiovascular risk [19], anemia, cognitive impairment [20], or neural tube defect 
[21,22]. Supplementation also improves physical performance of the same targeted 
population [23]. 
Vit.B6 has been shown to be important for normal cognitive function and in 
lowering the incidence of coronary heart disease among the elderly [24-26]. In 
addition, Vit.B6 supplementation has been shown to reduce diabetic complications and 
the incidences of neurodegenerative diseases in varying degrees [27]. Vit. B-6 includes 
pyridoxal, pyridoxine, and pyridoxamine, their intracellular conversion is shown in 
Figure 1, which function as essential cofactors for enzymes involved in various 
metabolic activities, which include amino acid, fat, and glucose metabolism [28]. The 
phosphate ester derivative pyridoxal 5’-phosphate (PLP) is the biologically active 
form of this vitamin [29] and reflects long-term body storage [30]. Figure 1 shows the 
intracellular conversion of vitamin B6 vitamers in the human body [31]. Studies have 
shown that low plasma PLP concentrations are associated with increased risk of 
cardiovascular disease (CVD) [32,33]. 
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Table 4: Coenzyme derivatives of B vitamins [12] 
Vitamin Coenzyme form 
Vitamin B1 (Thiamine) 
Vitamin B2 (Riboflavin)  
 
Vitamin B3 (Niacin)  
Vitamin B5 (Pantothenic acid)  
 
 
Vitamin B6 (Pyridoxine)  
 
Vitamin B7 (Biotin)  
Vitamin B9 (Folic acid)  
Vitamin B12 (Cyanocobalamin) 
Thiamine pyrophosphate (TPP) 
Flavin mononucleotide (FMN) 
Flavin adenine dinucleotide (FAD) 
Coenzyme A (CoA) 
Nicotinamide adenine dinucleotide (NAD) 
Nicotinamide adenine dinucleotide phosphate 
(NADP) 
Pyridoxal phosphate (PALP), Pyriodoxamine 
phosphate (PAMP) 
Biocytin 
Tetrahydrofolic acid (THFA) 
Deoxyadenosyl cobalamin 
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Table 5: Coenzyme reactions and consequences of deficiency that B vitamins 
are involved in 
 
Vitamin Coenzyme Typical reaction 
type 
Consequences of deficiency 
Thiamin (B1) Thiamine 
pyrophosphate 
Aldehyde transfer Beriberi (weight loss, heart 
problems, neurological 
dysfunction) 
Riboflavin (B2) Flavin adenine 
dinucleotide 
(FAD) 
Oxidation-reduction Cheliosis and angular stomatitis 
(lesions of the mouth), dermatitis 
Pyridoxine (B6) Pyridoxal 
phosphate 
Group transfer to or 
from amino acids 
Depression, confusion, 
convulsions 
Nicotinic acid 
(Niacin) 
Nicotinamide 
adenine 
dinucleotide 
(NAD+) 
Oxidation-reduction Pellagra (dermatitis, depression, 
diarrhea) 
Pantothenic 
acid 
Coenzyme A Acyl-group transfer Hypertension 
Biotin Biotin-lysine 
adducts (biocytin) 
ATP-dependent 
carboxylation and 
carboxyl-group 
transfer 
Rash about the eyebrows, muscle 
pain, fatigue (rare) 
Folic acid Tetrahydrofolate Transfer of one-
carbon components; 
thymine synthesis 
Anemia, neural-tube defects in 
development 
B12 5’-Deoxyadenosyl 
cobalamin 
Transfer of methyl 
groups; 
intramolecular 
rearrangements 
Anemia, pernicious anemia, 
methylmalonic acidosis 
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Recent data have shown that plasma PLP was adversely associated with 
inflammatory markers, which include C-reactive protein (CRP), fibrinogen, and blood 
cell count [33-36] Additionally, low vitamin B-6 concentrations are commonly present 
in diseases with a strong inflammatory basis, such as diabetes [37], rheumatoid arthritis 
[38], and inflammatory bowel disease [39]. Current evidence highlights the notion that 
inflammation may represent another link between vitamin B-6 and CVD. However, 
the relation of vitamin B-6 status with inflammation and other CVD risk factors has 
not been investigated extensively in a population at high risk of CVD [40]. 
Niacin, also known as vitamin B3 (Vit. B3), is an endogenous molecule having 
medicinal role. It is a precursor of coenzymes nicotinamide adenine dinucleotide 
(NAD) and nicotinamide adenine dinucleotide phosphate (NADP). These coenzymes 
trigger dehydrogenase reactions and have catalytic impact of many biomolecules [41]. 
Figure 2 shows the intracellular conversion of Vit B3 vitamers into NAD+ coenzyme.  
Niacin basically decreases low density lipoprotein cholesterol (LDL), very low-
density lipoprotein cholesterol (VLDL-C), and triglycerides (TG), but effectively 
increases high density lipoprotein cholesterol (HDL) [42]. Niacin alone [43] or in 
combination with other lipid lowering agents such as statin [44] or ezetimibe [45] 
significantly reduces risk of cardiovascular disease and arthrosclerosis progression 
[46] or hardening of the arteries. It lowers the risk of heart attacks. There is also some 
evidence that it might help in lowering the risk of Alzheimer's disease, cataracts, 
osteoarthritis, and type 1 diabetes [47]. On the other hand, type 2 diabetes is often 
attributed to an unhealthy lifestyle. 
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Figure 1: The different vitamin B6 vitamers and their intracellular conversions [31] 
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Figure 2: The different vitamin B3 vitamers and their intracellular conversions [1] 
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The current recommendation for the prevention and management of type 2 diabetes is 
a healthy, balanced diet, with particular focus on maintaining a healthy weight and 
physical activity [48]. Therefore, the benefit of isolated vitamins and their role in the 
prevention and treatment of type 2 diabetes continues to be a focus for research. 
According to the British National Formulary (BNF), nicotinic acid can be used in doses 
1.5–3 g daily to lower cholesterol and triglycerides by inhibiting synthesis, while 
raising high-density lipoprotein cholesterol [49]. It is often used in combination with 
a statin. A small number of studies have shown the beneficial effects of niacin on CV 
events in people with type 2 diabetes. 
Obesity is a risk factor for type 2 diabetes, cardiovascular diseases, cancer, 
pulmonary diseases, osteoporosis, periodontal diseases and has consequences on lipid, 
glucose and protein metabolism [50]. Obesity is a chronic disease of multifactorial 
origin that develops from the interaction of social, behavioral, psychological, 
metabolic, cellular, and molecular factors [51]. It is the condition under which adipose 
tissue is increased and can be defined as an increase in body weight that results in 
excessive fat accumulation. The World Health Organization (WHO) defines obesity 
as a body mass index (BMI) > 30 and defines overweight as with a BMI of 25 [52]. 
Adipose tissue is not only a triglyceride storage organ, but studies have shown 
the role of white adipose tissue as a producer of certain bioactive substances called 
adipokines. These adipokines induce the production of reactive oxygen species (ROS), 
generating a process known as oxidative stress (OS) [53]. The levels of inflammatory 
and oxidative stress markers were highly prevalent among overweight/obese Emirati 
women and this may predispose to increasing cardiovascular risks at relatively young 
age [54]. Therefore, the unbalanced diet that doesn’t provide the recommended daily 
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intake of vitamins and minerals can lead to health problems so we need a better 
promotion for lifestyle changes, both in normal weight and obese subjects [50]. 
Most published work on Vit.B6 is limited to general clinical observations and 
case studies. Although the role of Vit.B6 in reducing the complications associated with 
diabetes, aging, and neurodegenerative diseases has been widely reported [24,25,55-
56]. Based on the above, the current study investigates the levels of vitamins B3 and 
B6 in healthy and obese Emirati population in an attempt to correlate the levels of 
these vitamins with obesity. 
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1.5 Analysis of B vitamins and related biochemical compounds 
It is still well accepted and appreciated that accurate biochemical assessment 
will allow for more specific diagnosis. There is an obvious advantage in being able to 
detect biochemical signs of early or marginal deficiency. An individual who shows 
biochemical evidence of deficiency or inadequacy may be metabolically stable, and 
adequately adapted to his or her current intake, or maybe in the early stages of 
developing clinically significant deficiency disease. In population studies, whereas the 
number of people with clear clinical deficiency signs gives some indication of the scale 
of the problem, detection of the larger number who show biochemical signs of 
deficiency gives a better indication of the number of people at risk of developing 
deficiency, and hence a more realistic estimate of the true scale of the problem.  
Biochemical criteria of vitamin adequacy and methods for biochemical 
assessment of nutritional status can be divided into the following two distinct groups: 
1. The determination of the concentration vitamins and their metabolites in 
human plasma, urine, or tissue depends on the comparison of an 
individual/group with the population reference range, which is normally taken 
as the 95% confidence interval: twice the standard deviation about the mean 
value. By definition, 5% of the normal healthy population will lie outside the 
95% reference range. 
2. Metabolic loading tests and the determination of enzyme saturation with the 
cofactors measure the ability of an individual to meet his or her idiosyncratic 
requirements from a given intake, and, therefore, give a nearly absolute 
indication of nutritional status, without the need to refer to population reference 
ranges. A number of factors other than vitamin intake or adequacy can affect 
responses to metabolic loading tests. This is a particular problem with the 
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tryptophan load test for vitamin B6 nutritional status; a number of drugs can 
have metabolic effects that resemble those seen in vitamin deficiency or 
depletion, it is not known whether or not they could cause functional 
deficiency. 
The determination of water-soluble vitamins in various samples is rather 
difficult due to the chemical instability and complexity of the matrices in which they 
usually exist. As their chemical structures are not related, a considerable number of 
publications have appeared using different physical, chemical and biological methods 
to quantify them [57]. Most of the available analytical methods are time-consuming or 
not accurate. These techniques are based on the spectrophotometric, fluorimetric, 
enzymatic or microbiological properties of these vitamins assay techniques [57].  
           Capillary electrophoresis (CE) is one of the most popular chromatographic 
technique [58-61] along with high performance liquid chromatography (HPLC). These 
techniques are rapid, sensitive, accurate and have proven to be more effective for 
measurements of water-soluble vitamins concentration in pharmaceutical formulations 
[61-67]. The application of HPLC coupled with detectors ultraviolet/visible [61-65, 
67-73], fluorimetric [74-75] or electrochemical [76-80] are already available in in the 
literature. Critical factor for the development of HPLC methods is always the selection 
of the appropriate column and column packing material [81-85]. Most of the published 
methods are based on the gradient techniques [86-87], which can be very sensitive to 
pH changes of the mobile phase. 
Validated analytical methods for vitamin determination in pharmaceutical 
preparations such as tablets, capsules and oral solutions are mostly HPLC-based but 
individual methods for each different vitamin are also proposed [61]. Recently, a 
number of methods for the simultaneous determination of water-soluble vitamins have 
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been reported [72, 87-93], but the stability studies were not reported in details. Some 
of the HPLC methods have been used for the determination of vitamin-related 
compounds like thiamine and related compounds [68] as well as pyridoxine vitamers 
[94]. HPLC method for separation of pyridoxine vitamers, pyridoxic acid and its 
degradation product in plasma has also been published [95]. 
Depending on the compound of interest, some analytical standards have been 
well established years ago and are widely applied to quantify them in food and human 
blood samples. Microbiological methods have been traditionally used and, although 
this is currently changing, though they are still part of reference standards used for 
food control in different parts of the world [96-97]. Although these types of assays for 
vitamin analysis have been applied to the analysis of human serum or plasma, they 
present the disadvantage of providing an enormous result, without the possibility of 
differentiating between native vitamin used in food supplementation and its 
metabolites, which limits its application in clinical analysis. Other techniques are also 
applied for the analysis of food, such as the enzyme-linked immunosorbent assay 
(ELISA) [98], radio immunoassay (RIA) [99], protein-binding or biosensor based 
[100-102] with the same disadvantage on the differentiation of metabolites. 
Fluorescence detection combined with liquid chromatography has been extensively 
used to quantify B1 [103], B2 [104], B6 [105-106] and biotin [64] in foods and 
biological fluids but also used to validate multi-analyte methods in food matrices. For 
example, Heudi et al. reported a single chromatography for the quantification of 8 
water soluble vitamins used for fortification in premixes samples [107]. In the past ten 
years, liquid chromatography hyphenated with tandem mass spectrometry (LC-
MS/MS) has been demonstrated to be a more and more attractive technique with 
various advantages such as improved sensitivity and higher resolution for the analysis 
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of water soluble vitamins. The vitamins used for fortification and/or their naturally 
present vitamers are then quantified individually [108-109] or in multi-analyte 
methods [110-115]. Only few methods have been published for the analysis of water 
soluble vitamins in biological fluids such as human milk [105, 116], human plasma 
[104] or urine [117], where a single vitamin was quantified. More recent studies 
demonstrated the trend to go further into multianalyte methodologies [117]. For 
instance, in 2012, Hampel et al. quantified four different water soluble vitamins 
represented by five analytes in human milk by LC-MS/MS [118]. So far, an analytical 
approach for performing the simultaneous quantification of B1, B2, B3, B5, B6, B8 
and B9 and their main circulating forms in human plasma has not been published. This 
can be of a great advantage when vitamer profiling is required in large longitudinal 
studies [119]. 
High variability of vitamin B6 forms and their low concentration in human 
matrices cause difficulties in their accurate analysis [120]. Vitamin B6 status is 
typically assessed by measuring the level of one or more of the B6 vitamers in serum 
or plasma. Serum PLP is generally viewed as the best single indicator of B6 status. 
Serum or urinary 4-pyridoxic acid, the end product of vitamin B6 catabolism, is an 
indicator of recent intake. Vitamin B6 data are usually presented in the form of serum 
PLP and 4-pyridoxic acid, as generated by use of HPLC with post-column 
derivatization and fluorometric detection [121]. A cutoff value of 20 nmol/L is used to 
indicate low serum PLP concentrations. This cutoff value was used by the Institute of 
Medicine as the basis for the Estimated Average Requirement (EAR); however, it may 
overestimate the vitamin B6 requirement for health maintenance of more than half the 
group.  
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The biochemical assessment is usually conducted by means of chemical 
analysis of the vitamers, their metabolites and/or functional tests. Analytical 
techniques include determination of PLP in plasma and red cells. PLP metabolite, e.g. 
4-pyridoxic acid can be measured in urine or plasma, as well as the activity and 
activation coefficient with the red cell aminotransferases, and the tryptophan load 
metabolite test [122-123]. Combination of these markers provides a reliable approach 
for practical laboratory methods. Consequently, the use of microbiological [124-125], 
enzymatic and radio-enzymatic [126-129], spectrofluorometric [130] and liquid 
chromatographic methods [131] has been reported for this purpose. 
The majority of separation procedures is achieved by the use of reversed-phase 
high-performance liquid chromatography (HPLC) coupled with fluorescent [132] and 
UV [133] detections. Corbun and Mahuren [134] reported a cation-exchange HPLC 
procedure, involving a gradient elution and a post-column bisulfide derivatization 
followed by fluorescence detection that was suitable for quantifying B6 components 
in human plasma. Some other methods have been also used to enhance the 
fluorescence of PL and PLP by bisulfide adduct formation [135], formation of 
semicarbazones by reaction with semicarbazide [136], and oxidation by cyanide to 
carboxylic acid [137-139]. Modified fluorescent methods eliminated cyanide by post-
column conversion of PLP to 4-pyridoxic acid and 5-phosphate by chlorite [140]. 
Midttun et al. [141] reported the potential of liquid chromatography combined with 
tandem mass spectrometry (LC–MS) for the quantification of all known forms of 
vitamin B6 and riboflavin in human plasma. There were also other successfully 
validated methods of vitamin B6 detection based on a redox reaction with 
electrochemical detectors, i.e. amperometric or coulometric detectors. The oxidation 
of PN at a carbon paste electrode has been firstly examined. Consequently, 
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modification of the glassy carbon electrodes, flow and sequential injection techniques 
improved speed and selectivity as compared with electrochemical assays [79]. The 
chemical structure of all the particular vitamin B6 forms enables their measurement 
by electrochemical detection at nanomolar concentrations in endogenous plasma and 
serum. It should be mentioned that use of electrochemical detection has been already 
reported in literature [57]. However, such application was limited to samples other 
than pharmaceuticals and foods. 
Accurate determination of all forms of vitamin B6 is essential for assessing 
nutritional and metabolic requirements and the metabolism of this vitamin. However, 
the task of measuring these forms becomes quite difficult because of the complexity 
of the biological matrix and the extremely low concentration of these compounds in 
plasma (nanomoles per liter or less) [142]. A number of methods have been developed 
for the assay of B6 vitamers in plasma for clinical and nutritional purposes. These 
include microbiological, enzymatic, or chemical methods and more recently high 
performance liquid chromatography (HPLC) [143]. 
Vitamin B6 forms in serum are most commonly measured by high performance 
liquid chromatography (HPLC) with fluorometric detection; chemical derivatization 
(sample, online, or post-column) is almost always used to enhance PLP fluorescence 
[121]. Enzymatic (radioactive or nonradioactive) and microbiological methods have 
also been employed [141]. The comparability of methods could be improved [144]; 
such improvement is expected to occur in the future due to the new availability of 
NIST SRM 1950 and 3950 (certified concentrations for serum PLP by LC-MS/MS). 
Today HPLC procedures with appropriate detection systems are regarded as the most 
convenient method for the evaluation of vitamin B6 nutritional status. Several HPLC 
procedures for the assay of B6 vitamers have been reported; however, most suffer from 
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inadequate resolution and lack of sensitivity [144-147]. Furthermore, it is difficult to 
adopt some of these methods in the routine setup because of the unavailability of 
columns used [148]. It is also important to note that except very few studies [148], 
little attention has been paid for the accuracy and imprecision of the assays. 
Clinical analysis of vitamin B6 is accomplished at present by a variety of 
enzymatic assays and HPLC methods [149]. Although some direct comparisons of 
these methods can be found in the literature (usually in the form of comparing results 
from a new method with an established one as a part of method validation), objective 
comparative studies of vitamin B6 measurements among several methods or 
laboratories are rare. The only previously published account of a multi-laboratory 
comparative study of vitamin B6 measurements in human biological specimens was 
conducted by Reynolds in 1983 [150], in which a single pooled plasma sample was 
sent to 14 US laboratories routinely performing B6 analyses. Results from this study 
showed a wide range of values for the B6 vitamer and metabolite content of the 
specimen. For pyridoxal 5-phosphate (PLP), the primary circulatory form of vitamin 
B6, six different laboratories using enzymatic methods reported concentrations of 53–
65 nmol/L for the specimen; the remaining laboratories, using HPLC, found PLP 
concentrations of 48–1700 nmol/L. 
The biggest advantage of an LC–MS/MS method is the simple work up, only 
protein precipitation under acidic conditions is needed before the sample could be 
injected. This is in sharp contrast to HPLC methods, where derivatization of both 
molecules is required because of the lack of a fluorophore in their chemical structures 
[151]. However, it is still challenging to transfer an existing LC–MS/MS method to 
another system without additional optimization. The choice of column, mobile phase, 
gradient and MS-settings are very delicate matters and often it comes down to 
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redeveloping the method for the new setup [152]. Furthermore, every laboratory has 
its own routines and preferences, mostly dictated by other tests that are run on the same 
MS/MS system.  
 
1.6 Aim of the study 
               Based on the above, the main objectives of the current work are to: 
1. Develop a sensitive robust and easy LC-MS/MS based assay for measuring 
vitamins B6 and B3 in human plasma. 
2. Use the above method to measure plasma vitamins B6 and B3 in healthy and 
obese Emirati population. 
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Chapter 2: Materials and Methods 
2.1 Materials 
            Vitamin standards and other reagents were purchased from different suppliers: 
Pyridoxal -5’- phosphate hydrate, Pyridoxal hydrochloride, Pyridoxamine -5’-phosphate, 
Nicotinamide, Phosphate buffered saline, Tris(2-carboxyethyle)phosphate 
hydrochloride, Heptafluorobutyric acid, Trichloroacetic acid, Formic acid, and LC-MS-
grade water were purchased from Sigma-Aldrich, USA. Pyridoxine hydrochloride was 
purchased from Supelco and Pyridoxamine dihydrochloride was purchased from Fluka, 
USA. While HPLC-grade acetonitrile was purchased from Merck, USA. 
 
2.2 Methods 
2.2.1 Preparation of standard solutions 
 
Stock individual solutions of all B6 vitamers, B3 and internal standards were 
prepared at 1000 ppm (1µg/ml) in deionized water. These stock solutions were kept in 
Eppendorf tubes and stored at -80℃ to avoid degradation. Working solutions of 
vitamins standards were prepared daily by mixing and diluting individual stock 
solutions in DI water to desired concentrations. Preparation steps were protected from 
light during laboratory handling by using amber tubes to prevent vitamins from 
degradation. 
 
2.2.2 Plasma sample extraction method 
 
Plasma samples from the test subjects were stored at -80℃, were thawed right 
before the analysis. An aliquot of 300 l was taken into an Eppendorf tube and spiked 
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with 10 l of the internal standard (100 ppm) then the mixture was vortexed for 2 
minutes. The proteins were precipitated by adding an equal volume of 0.6 N TCA to 
produce a final TCA concentration of 0.3 N. The samples were vortexed for 2 minutes 
and then incubated for 5 minutes at 50℃. The samples were then centrifuged at 11,000 
rpm for 10 minutes at 4℃. The resulting supernatant was filtered using CA filter 
(0.22m) then transferred into HPLC amber vials and placed in an autosampler where 
the samples were kept at 4℃ and protected from light. Normally, 8 l of sample extract 
was injected into LC-MS/MS system. 
 
2.2.3 Liquid chromatography and mass spectrometry 
 
LC separation of vitamins was achieved with Agilent 1260 HPLC-system on a 
reversed-phase column Poroshell 120 EC-C18 (Agilent Technology, Santa Clara, CA, 
USA) with a particle size 2.7 m, an inner diameter of 3.0 mm and a length of 100 
mm. The column was maintained at 35oC and a constant flow rate of 0.4 ml/min. Two 
mobile phases were used: A was LC-MS grade water containing 0.1% Formic acid and 
0.1% Heptafluorobutyric acid, and B, which was Acetonitrile containing 0.1% Formic 
acid. The LC method was set as follow: 3 min of 100% A, followed by a 0-100% 
gradient of B from 3-5 min, then 100% of B from 5-8:50 min and ended with 100% A 
from 8:60 - 10 min, followed by 100% A for 5 min as post run.  Mass spectrometry 
analysis was performed on an Agilent 6420 Triple Quadrupole MS system in positive 
electrospray ionization (ESI+) mode. Electrospray voltage was set at 4 kV, Ion source 
gas 1 (desolvation gas consisting of nitrogen 99.9%) pressure was set at 20 psi, ion 
source gas 2 (nebulizer gas consisting of nitrogen) was set at 45 psi and the drying gas 
(N2) flow was 8 L/min at 325℃. Table 6 shows the precursor and product ions along 
with their collision energies. 
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    Table 6: Shows names, structure, mass, precursor and product ions along with 
    collision energies 
 
Name Vitamer Structure 
Mass 
(g/mol) 
Precursor 
ion 
(m/z) 
Product 
ion 
(m/z) 
Collision 
energy 
(eV) 
Pyridoxal-5'- 
phosphate 
(PLP) 
 
 
 
 
C8H10NO6P 
247 248 149.7 
 
 
15 
Pyridoxal 
hydrochloride 
(PL) 
 
 
 
 
C8H9NO3 · HCl 
203.63 
167.06 
(-HCl) 
168 149.9 
 
 
10 
Pyridoxamine 
dihydrochloride 
(PM) 
 
 
 
 
C8H12N2O2 · 2HCl 
241.11 
168.09 
(-2HCl) 
169 152 
 
10 
Pyridoxamine-5'-
phosphate 
(PMP) 
 
 
 
 
C8H13N2O5P 
248 249 232.1 
 
10 
Pyridoxine 
hydrochloride 
(PN) 
 
 
 
 
C8H11NO3 · HCl 
205.64 
169.07 
(-HCl) 
170 151.9 
 
 
10 
Nicotinamide  
 
 
C6H6N2O 
 
122.12 
 
123 
 
80.2 
 
 
20 
Pyridoxine-
(methyl-d3) 
hydrochloride 
 
 
 
 
 
C8D3H8NO3·HCl 
 
208.6 
 
173 
 
155 
 
 
 
 
10 
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Chapter 3: Results and Discussion 
3.1 Development of LC-MS/MS-based method 
An extraction approach for vitamins B6 and B3 was developed after trying 
many extraction techniques along with developing a sensitive and robust LC-MS/MS 
method for analysis of these metabolites.  
In the following sections, the sequence of the experiments that have been carried 
out in this regard will be discussed. It started with the identification of product ions 
of each precursor ions of each analyte. This was followed by checking the effect of 
varying the multiplier voltage (Delta EMV) on the intensity of the peaks produced. 
Then, the effect of changing the types of columns on the resolutions of the obtained 
peaks was also investigated. During experimental procedure, the selected incubation 
conditions were tested in order to improve the yield of our analytes. In addition to the 
above, the reproducibility of our method were also tried and tested along with testing 
the recovery of all analytes. 
Based on the detailed study of the above mentioned parameters an optimization 
of the method was reached and evaluated.  
 
3.2 Multiple reaction monitoring (MRM) (precursors and product ions   
identification) 
Compounds with different structures respond differently to the fragmentor 
setting. The ideal fragmentation voltage for each component was detected through the 
injection of individual standards. The fragmentor was set up in positive mode. Based 
on the mass of the standards under different collision energies, daughter ions were 
detected. The following components were found to be matching those found in the 
literature: Nicotinamide, pyridoxamine (PM), pyridoxamine 5-phosphate (PMP) 
31 
 
 
 
[119], and pyridoxal 5-phosphate (PLP) [153]. Other vitamers including, pyridoxal 
(PL) and pyridoxine (PN) were found to be close to the values found in the literatures 
[119].  
The following Figures illustrate the Electrospray ionization (ESI) product ions, 
at different collision energies (CE), of each analytes. In Figures 3a, b and c of PLP 
shows that the precursor ion m/z (248) was not fragmented properly but in 3d the 
fragmentation was occurred and product ion m/z (149.7) signal was high intensity at 
collision energy eV (15). In Figure 4c of PL, the precursor ion m/z (168) was totally 
fragmented and gave a very intensive peak m/z (149.9) at collision energy eV (10). 
Figure 5b shows the precursor ion m/z (232.1) of PMP is clearly detected at collision 
energy eV (10). In Figure 6b, the intensity of product ion m/z (152) of PM m/z (169) 
was obtained at collision energy eV (10). In Figure 7(d), the product ion of PN m/z 
(151.9) was the strongest one at collision energy eV (10). For Nicotinamide precursor 
ion m/z (123), the high intensity product ion was m/z (80.2) which is detected at 
collision energy eV (20) at which the precursor ion is totally fragmented shown in 
Figure 8d. The daughter ions of the internal standard PN-d3 m/z (173) in Figure 9d 
was detected at collision energy eV (10). The precursor and product ions as well as 
the fragmentor voltage and collision energies values determined for the various 
analytes are summarized in Table 7. 
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Figure 3: ESI Fragmentation of PLP of different collision energy (CE), Asterisk (*) 
refers to the precursor ion, followed by a schematic showing the fragmentation of 
the PLP molecule and the structure of the precursor and daughter ions 
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          Figure 4: Fragmentation of PL of different collision energy (CE),  
Asterisk (*) refers to the precursor ion, followed by a schematic showing the 
fragmentation of the PL molecule and the structure of the precursor and daughter ions 
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Figure 5: ESI Fragmentation of PMP of different collision energy (CE), 
Asterisk (*) refers to the precursor ion, followed by a schematic showing the 
fragmentation of the PMP molecule and the structure of the precursor and 
daughter ions 
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Figure 6: ESI Fragmentation of PM of different collision energy (CE), 
Asterisk (*) refers to the precursor ion, followed by a schematic showing the 
fragmentation of the PM molecule and the structure of the precursor and 
daughter ions 
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Figure 7: ESI Fragmentation of PN of different collision energy (CE), Asterisk 
(*) refers to the precursor ion, followed by a schematic showing the 
fragmentation of the PN molecule and the structure of the precursor and  
daughter ions 
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Figure 8: ESI Fragmentation of Nicotinamide of different collision energy 
(CE), Asterisk (*) refers to the precursor ion, followed by a schematic showing 
the fragmentation of the Nicotinamide molecule and the structure of the 
precursor and daughter ions 
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Figure 9: ESI Fragmentation of PN-d3 of different collision energy (CE), Asterisk 
(*) refers to the precursor ion, followed by a schematic showing the fragmentation 
of the PN-d3 molecule and the structure of the precursor and daughter ions 
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Table 7: Summary of fragmentation parameters identified for all analytes examined 
in this study 
 
Analyte 
 
Precursor 
ion 
(m/z) 
Product ion 
(m/z) 
Fragmentor 
voltage 
(V) 
Collision 
energy 
(eV) 
PLP 248.0 149.7 45 15 
PL 168.0 149.9 94 10 
PMP 249.0 232.1 45 10 
PM 169.0 152.0 94 10 
PN 170.0 151.9 94 10 
Nicotinamide 123.0 80.2 94 20 
PN-d3 173.0 155.0 94 10 
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3.3 Effect of changing delta values on signal response in the MS 
The multiplier voltage (Delta EMV) is a parameter that significantly affect the 
response in MS. In this study, different Delta values were tested by varying the voltage 
from 0, 250, 500 to 750 to study its effect on the MRM signal. As can be seen from 
Table 8 below, increasing the multiplier voltage, the response resulted in being 
increased.  However, we decided to work with Delta 0 as recommended by the Agilent 
engineer to avoid damaging the instrument in the long term. Table 8 showed that Delta 
0 still gave fairly high AUC which is acceptable for our analytes extraction.  
 
3.4 The chromatographic behavior of analytes on two different columns 
 
The chromatographic separation method was tested using two types of columns 
with different dimensions and similar packing materials. The first one was Eclipse plus 
C-18 with a particle size 1.8µm, an inner diameter of 2.1 and a length 50mm, and the 
second one was Poroshell 120 EC-C18 with a particle size 2.7µm, an inner diameter 
of 3.0 mm and a length of 100 mm. Our main reason for testing both columns was to 
see which one will give most separated peaks in term of high resolution and intensity. 
Both columns showed almost the same number of peaks but the elution profiles 
were different. However, as we can see in Figure 10, the chromatographic profile 
obtained with Poroshell column was well separated peaks with high intensity as 
opposed to chromatographic profile of Eclipse plus C-18 column with separated 
broadening peaks (Figure 11). 
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   Table 8:  Effect of increasing the Delta voltage on the area under the curve (AUC) 
   for each analyte tested 
 
Analyte MRM Delta 0 Delta 250 Delta 500 Delta 750 
PMP 249>232.1 414,305 469,594 955,609 1,780,831 
PLP 248>149.7 63,730 207,145 403,275 770,029 
PN 170>151.9 1,709,620 3,539,634 7,407,309 15,067,360 
PM 169>152 686,300 1,243,534 2,700,818 5,550,861 
PL 168>149.9 2,007,130 3,027,106 6,383,150 13,206,124 
Nicotinamide 123>80.2 1,185,862 4,962,476 10,104,322 20,785,448 
PN-d3 173>155 2,908,068 5,661,739 11,718,680 23,616,674 
. 
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Figure 10: The chromatographic profile of 8 analytes on Poroshell column 
 
 
 
Figure 11: The chromatographic profile of 8 analytes on Eclipse plus C-18 column 
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3.5 Protein precipitation and liberation of the analytes 
Since the final application of our assay was the analysis of vitamins B6 and B3 
in human plasma. We also wanted to determine the best method for the extraction of 
these vitamins from plasma. The precipitating agent [154-155] and incubation 
conditions [156] are known to generally influence the effectiveness of protein 
precipitation and analyte extraction. Trichloroacetic acid (TCA) has been reported to 
be effective in precipitating human plasma [154-155]. However, it is also known that 
some vitamers, such PLP, is strongly bound [157-158] and requires vigorous vortexing 
as well as incubation condition at 50oC for their complete release. Therefore, 
incubation conditions were tested to determine which condition will give the highest 
yield of our analytes from spiked simulated plasma in the present study. Three different 
conditions were tested: room temperature, 50℃ and 0℃. 
As can be seen in Figure 12, there was not much difference in the 
chromatographic profile between ice condition and other conditions. However, the 
integration of each peak of the three conditions exhibited different areas under the 
curve (AUC). As can be seen in Table 9, the AUC, on ice, of PLP is 36480 which is 
lower than other two conditions. However, the AUC, at room temperature, and AUC, 
at 50oC, 41076, 41229 respectively are showing slight difference. The other analytes 
show similar results. The significant difference between room temperature and 50℃ 
conditions is that the former temperature was carried out in an hour while the latter 
one was carried out in 5 minutes. Therefore, performing the experiment at 50℃             (5 
min) was selected as an optimum condition. 
The second step was testing these three conditions on plasma sample. Table 10 
shown the values of the area under the curve. It is evident that the difference between 
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the two conditions can be demonstrated through the higher AUC at 50℃ than the AUC 
of room temperature incubation condition in all analytes.  
 
 
   Figure 12: The chromatograms showing the intensity of recovered vitamins under the 
three different incubation conditions 
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        Table 9: Area under the curve (AUC) of all analytes in simulated plasma under 
        different extraction conditions 
 
Analyte 
0℃ 
(I hour) 
25℃ 
(1 hour) 
50℃ 
(5 min) 
PMP 16,599 20,120 21,931 
PLP 36,480 41,076 41,229 
PN 222,146 234,575 245,534 
PM 212,681 243,573 264,702 
PL 230,989 277,679 275,796 
Nicotinamide 240,934 313,138 352,393 
 
     Table 10: Area under the curve (AUC) of all analytes of human plasma samples 
     under various conditions 
 
Analyte 
25℃ 
(1 hour) 
50℃ 
(5 min) 
PMP 15 56 
PLP 10 37 
PN 420 674 
PM 263 728 
PL 547 1,319 
Nicotinamide 1,166 2,450 
PN- d3 (spiked) 159,727 186,662 
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3.6 Test of reproducibility 
             Analytes are sensitive to light so that all the experiments were performed in 
dark and the analytes were kept in amber glassware. All stock solutions were kept at  
-80℃. The amount used in every experiment was prepared daily and kept in 4℃ for 
few days if needed. Therefore, reproducibility test was also done to ensure the 
reproducibility of the analytes within two days and after one week. 
 As can be seen in Figure 13 the chromatograms after one day and in Figure 14 
chromatogram after one week that there is no significant change in the intensity of the 
peaks which improve the stability and reproducibility of the analytes. 
 
 
       Figure 13: LC-MS/MS chromatograms of 8 analytes under optimized conditions    
       (Day 1) 
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     Figure 14: LC-MS/MS chromatograms of 8 analytes under optimized conditions    
    (Day 2) 
 
 
     Figure 15: LC-MS/MS chromatograms of 8 analytes under optimized conditions   
     (Day 7) 
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3.7 The optimized parameter for the LC-MS/MS method  
               Originally, our aim was to reach a method conditions to enhance the 
liberation of our analytes from protein bounded components in plasma, the next goal 
is to reach a separation method which can give well separated peaks with high 
resolution. In Table 11 shown below, a list of the optimized conditions is represented. 
After reaching our optimized conditions, they were used in the investigation of the 
analyses’ recoveries. This was carried out by analysis of spiking TCA samples (Figure 
16) and simulated plasma (Figure 17). The asterisk (*) in both figures refers to a peak 
which could most likely be an isomer of PL as it is only shown in the extracted MRM 
chromatogram of this analyte (MRM 168  149.9). 
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Table 11. The optimized conditions of LC-MS/MS and the method 
LC system Agilent technologies 1260  series LC system 
Column Poroshell 120 EC-C18, (3.0 × 100 mm) 
Column temperature 35℃ 
Autosampler 
temperature 
4℃ 
Mobile phase A 0.1% formic acid and 0.1% Heptafluorobutyric acid in 
water 
Mobile phase B  0.1% formic acid in Acetonitrile 
Flow rate 0.4 mL/min 
Injection volume 8 µL 
MS conditions 
 
6420 Triple Quad, dry gas flow 8 L/min, dry gas 
temperature 325℃, nebulizer pressure 45 psi, capillary 
voltage 4000 V 
Gradient 
 
              Time           %A               %B 
              0 min        100.0%            0.0% 
           3.0 min        100.0%            0.0% 
           5.0 min            0.0%        100.0% 
           8.5 min            0.0%        100.0% 
           8.6 min        100.0%            0.0% 
         10.0 min        100.0%            0.0% 
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     Figure 16: LC-MS/MS chromatogram of all analytes in neat solution in optimized 
     LC-MS/MS method 
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Figure 17: LC-MS/MS chromatogram of all analytes in simulated plasma solution in  
optimized LC-MS/MS method 
 
 
     Table 12: Percentage recovery of all analytes in simulated plasma using TCA and 
     50℃ (5 min) incubation 
 
Analyte Recovery (%) Standard deviation 
PLP 121.3 19.2 
PM 82.5 1.8 
PL 118.0 25.6 
PN 102.8 2.6 
PMP 100.8 34.1 
Nicotinamide 83.6 9.2 
PN-d3 95.2 2.6 
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3.8 Calibration curves 
            The calibration curves were built after preparing and running different 
concentrations of all analytes and internal standard, both spiked in simulated plasma 
and measuring the instrumental response of each concentration. The data shown in 
Figures 17-22 of all analytes investigated in this study show a linear response in the 
low range (a) and the high range (b). The square of the correlation coefficient (r2) 
values were over 0.93, which means that most of the y values were not away from the 
predicted line. The error bars found in certain graphs were from repeated 
measurements of the same sample and are standard deviation. The lower limit of 
detection (LLOD) and quantification (LLOQ) of all analytes were determined and 
represented in Table 13. 
               The calibration curves shown in Figures 18-23 were used to interpret the 
concentrations of these analytes in unknown samples, as will be discussed in the 
following sections.    
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Figure 18: Low range (a) and high range (b) calibration curves of PLP 
54 
 
 
 
 
Figure 19:  Low range (a) and high range (b) calibration curves of PL 
55 
 
 
 
 
Figure 20: Low range (a) and high range (b) calibration curves of PMP 
56 
 
 
 
 
Figure 21: Low range (a) and high range (b) calibration curves of PM 
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Figure 22: Low range (a) and high range (b) calibration curves of PN 
 
58 
 
 
 
 
Figure 23:  Low range (a) and high range (b) calibration curves of Nicotinamide 
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     Table 13: The lower limit of detection and the lower limit of quantification of  
     each analyte 
 
Analyte LLOD (pg) LLOQ (pg) 
PLP 0.66 56.0 
PL 6.0 18.4 
PMP 6.0 184.0 
PM 18.0 56.0 
PN 2.0 6.0 
Nicotinamide 4,400 4,400 
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3.9 Analysis of human plasma samples 
3.9.1 Health patients’ plasma samples 
            Figure 24 show the concentrations of the analytes that were detected in unknown 
human plasma samples of healthy patients. A total of fifty-seven (57) healthy human 
plasma samples were analyzed in this study. It should be mentioned that PM analyte 
was not detected in all samples while other analytes including PMP, PLP, PN, PL, and 
nicotinamide were detected with different extents. Figure 24a shows that the average 
concentration of PMP analyte in all 57 samples was around 30 nM, where patients 
samples showed an even distribution around this average. The PLP analyte was 
detected in the plasma samples of 14 patients only with an average concentration of 
36 nM, while PLP was not detected in the samples of the remaining 43 samples, as 
shown in Figure 24b. On the other hand, PN and PL analytes were detected in the 
plasma samples of all 57 patients with average concentrations of 21 and 45 nM, 
respectively, as shown in Figures 24c and d. Finally, nicotinamide analyte was 
detected in 54 samples only with an average concentration of 850 nM, as shown in 
Figure 24e. A detailed quantification of the concentrations of these analytes is shown 
in Table 14. 
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Figure 24:  Concentrations of PMP, PL, PN, PL and Nicotinamide in healthy Emirati 
population (n=57) 
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     Table 14: Quantification of B3 and B6 vitamers in 57 unknown healthy plasma  
     samples 
 
  PMP PLP PN PM PL Niacin 
Sample Concentration (nM) 
1 42.9 n.d. 25.6 n.d. 20.3 1365.0 
2 36.5 35.3 25.0 n.d. 84.3 544.9 
3 21.0 n.d. 18.1 n.d. 66.8 2600.6 
4 35.9 30.6 13.3 n.d. 53.8 1035.9 
5 29.7 n.d. 19.2 n.d. 24.5 2492.7 
6 21.4 23.5 14.9 n.d. 33.6 1338.1 
7 30.7 17.6 12.7 n.d. 34.3 776.9 
8 20.0 n.d. 12.3 n.d. 32.6 949.6 
9 18.6 18.8 13.3 n.d. 23.8 2881.2 
10 36.3 n.d. 11.3 n.d. 27.5 1138.4 
11 21.6 n.d. 9.9 n.d. 31.1 3032.2 
12 21.4 n.d. 15.7 n.d. 21.6 588.1 
13 13.8 n.d. 17.0 n.d. 22.6 1143.8 
14 17.1 38.4 9.5 n.d. 44.5 393.9 
15 18.1 n.d. 22.4 n.d. 13.8 884.8 
16 28.2 n.d. 23.2 n.d. 51.4 491.0 
17 23.7 n.d. 18.4 n.d. 53.3 841.7 
18 34.2 n.d. 22.7 n.d. 50.2 286.0 
19 33.6 n.d. 16.3 n.d. 44.6 701.4 
20 35.0 20.0 20.9 n.d. 58.6 1251.7 
21 23.3 n.d. 30.8 n.d. 57.7 458.6 
22 30.7 90.5 28.7 n.d. 130.1 n.d. 
23 30.9 n.d. 21.6 n.d. 46.7 669.0 
24 27.2 30.6 21.6 n.d. 53.6 1381.2 
25 38.3 n.d. 19.8 n.d. 42.7 415.4 
26 29.3 n.d. 19.4 n.d. 43.9 577.3 
27 45.1 n.d. 19.9 n.d. 44.0 863.3 
28 19.0 n.d. 21.9 n.d. 11.3 604.3 
29 52.2 n.d. 18.3 n.d. 53.0 750.0 
30 56.9 n.d. 13.1 n.d. 32.7 1084.5 
31 82.3 38.0 17.5 n.d. 60.1 825.5 
32 47.4 n.d. 21.0 n.d. 38.5 1165.4 
33 51.7 n.d. 19.5 n.d. 32.2 1764.3 
34 21.4 n.d. 22.0 n.d. 46.5 2390.2 
35 26.6 18.8 19.4 n.d. 37.7 6005.1 
36 35.9 68.9 19.1 n.d. 95.9 3620.3 
37 41.2 n.d. 19.1 n.d. 32.5 830.9 
38 27.4 n.d. 22.2 n.d. 42.0 965.8 
39 13.8 n.d. 19.9 n.d. 42.0 1705.0 
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      Table 14: Quantification of B3 and B6 vitamers in 57 unknown healthy plasma 
     samples (continued) 
 
  PMP PLP PN PM PL Niacin 
Sample Concentration (nM) 
40 11.3 n.d. 22.8 n.d. 39.7 690.6 
41 13.8 n.d. 20.3 n.d. 41.2 572.7 
42 10.9 n.d. 21.7 n.d. 47.9 793.1 
43 20.2 n.d. 21.0 n.d. 32.9 2303.8 
44 26.6 n.d. 17.5 n.d. 48.9 n.d. 
45 14.6 n.d. 19.3 n.d. 50.7 566.5 
46 19.2 n.d. 22.1 n.d. 52.1 1348.9 
47 35.9 37.6 24.3 n.d. 88.8 1980.1 
48 15.9 n.d. 26.6 n.d. 43.3 n.d. 
49 63.3 n.d. 27.1 n.d. 41.2 588.1 
50 16.7 n.d. 28.2 n.d. 52.3 372.3 
51 28.4 n.d. 26.0 n.d. 49.5 755.4 
52 22.7 n.d. 30.1 n.d. 52.2 1429.8 
53 21.4 n.d. 31.8 n.d. 49.0 302.1 
54 55.9 35.6 32.4 n.d. 58.2 388.5 
55 29.9 n.d. 33.2 n.d. 48.4 275.2 
56 43.1 n.d. 28.5 n.d. 36.0 825.5 
57 30.1 n.d. 30.3 n.d. 43.7 1143.8 
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3.9.2 Obese patients’ plasma samples 
              Similarly, a total of fifty seven (57) unknown human plasma samples of obese 
patients were also analyzed for the concentrations of the analytes in these samples. 
Figure 25 shows the analysis results of five analytes (PMP, PLP, PN, PL, and 
nicotinamide), while PM analyte was not detected in all plasma samples. All plasma 
samples showed variable concentrations of PMP analyte with an average value of 50 
nM, as shown in Figure 25a. On the other hand, the concentration of PLP analyte was 
detected in the plasma samples of 8 patients only with an average value of 37 nM, as 
shown in Figure 25b. The concentrations of PN and PL analytes were detected in the 
plasma samples of all obese patients, with average concentrations of 21 and 61 nM, 
respectively, as shown in Figures 25 c,d. Finally, the concentration of nicotinamide 
analyte was detected in a total of 45 samples with an average value of 3700 nM. A 
detailed quantification of the concentrations of these analytes is shown in Table 15. 
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Figure 25:  Concentrations of PMP, PL, PN, PL and Nicotinamide in obese Emirati 
population (n=57) 
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      Table 15: Quantification of B3 and B6 vitamers in 57 unknown obese plasma  
      samples 
 
 PMP PLP PN PM PL Niacin 
Sample Concentration (nM) 
1 12.0 n.d. 24.7 n.d. 51.5 5471.0 
2 34.4 n.d. 20.8 n.d. n.d. 1823.7 
3 13.6 n.d. 21.7 n.d. 48.4 1348.9 
4 n.d. n.d. 39.5 n.d. n.d. n.d. 
5 64.3 26.2 20.9 n.d. 114.9 2314.6 
6 27.8 n.d. 20.1 n.d. 58.3 1246.3 
7 69.1 n.d. 21.0 n.d. 46.4 3118.6 
8 14.2 n.d. 26.3 n.d. 62.2 1516.1 
9 79.2 29.8 25.8 n.d. 74.7 2514.3 
10 37.1 n.d. 23.8 n.d. 57.0 n.d. 
11 36.1 30.2 27.2 n.d. 41.7 n.d. 
12 28.7 n.d. 24.5 n.d. 45.4 n.d. 
13 46.4 n.d. 23.4 n.d. 57.9 n.d. 
14 15.0 n.d. 23.6 n.d. n.d. 2044.9 
15 14.4 n.d. 30.8 n.d. n.d. 2217.5 
16 24.1 n.d. 25.8 n.d. n.d. 2854.2 
17 31.3 36.8 21.2 n.d. 70.0 3177.9 
18 77.9 n.d. 35.3 n.d. 63.1 2082.6 
19 15.9 69.3 28.7 n.d. 95.1 3679.7 
20 33.2 n.d. 24.4 n.d. 41.2 3323.6 
21 20.6 n.d. 26.1 n.d. 57.6 n.d. 
22 24.3 61.5 21.3 n.d. 97.3 1818.3 
23 22.5 n.d. 20.3 n.d. 41.4 5956.5 
24 18.6 n.d. 21.1 n.d. 41.1 6167.0 
25 59.8 n.d. 28.0 n.d. 40.7 2271.5 
26 42.9 n.d. 29.1 n.d. 86.2 1645.6 
27 18.3 n.d. 22.4 n.d. 41.5 4526.8 
28 33.2 n.d. 25.0 n.d. 40.0 3275.0 
29 21.2 n.d. 23.4 n.d. 70.1 4402.7 
30 16.1 n.d. 20.6 n.d. 54.3 3258.8 
31 77.3 n.d. 12.6 n.d. 56.7 5287.5 
32 32.4 22.7 11.8 n.d. 62.6 8810.7 
33 94.8 n.d. 14.3 n.d. 59.0 2401.0 
34 86.0 n.d. 14.8 n.d. 35.8 1494.5 
35 38.8 n.d. 24.3 n.d. 93.9 5406.2 
36 243.9 n.d. 18.0 n.d. 63.6 9625.4 
37 138.3 n.d. 20.7 n.d. 65.3 11303.4 
38 44.3 n.d. 12.1 n.d. 76.3 5109.5 
39 100.6 n.d. 12.0 n.d. 58.3 4337.9 
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     Table 15: Quantification of B3 and B6 vitamers in 57 unknown obese plasma 
     samples (continued) 
 
 PMP PLP PN PM PL Niacin 
Sample Concentration (nM) 
40 95.4 n.d. 6.7 n.d. 75.6 3345.2 
41 101.0 n.d. n.d. n.d. 58.3 4105.9 
42 47.8 n.d. 20.7 n.d. n.d. n.d. 
43 25.6 n.d. 17.6 n.d. n.d. 3998.0 
44 34.8 n.d. 21.8 n.d. n.d. 3064.6 
45 90.9 n.d. 16.4 n.d. n.d. 3933.3 
46 168.2 27.8 21.3 n.d. 60.6 1386.6 
47 17.5 n.d. 19.2 n.d. n.d. 7181.3 
48 27.2 n.d. 12.7 n.d. 25.2 10693.7 
49 191.9 n.d. 7.7 n.d. n.d. 372.3 
50 65.3 n.d. 13.5 n.d. n.d. 2832.6 
51 53.8 n.d. 15.4 n.d. n.d. 2498.1 
52 19.8 n.d. 14.0 n.d. n.d. 3884.7 
53 39.0 n.d. 7.8 n.d. n.d. 3965.6 
54 87.2 n.d. 12.9 n.d. n.d. 933.4 
55 26.8 n.d. 9.5 n.d. n.d. 2476.5 
56 54.6 n.d. 11.4 n.d. n.d. 2633.0 
57 23.7 n.d. 8.8 n.d. n.d. 3539.4 
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            A comparative analysis was also carried out between the concentrations of the 
analytes found in the plasma samples of healthy versus obese patients. We also 
compared our data with a representative data set of vitamin concentrations in healthy 
human plasma previously published by Redeuil et al in 2015 [119], Table 16. 
Compared with an average normal concentration of 4.9 nM PMP (as published by 
Redeuil et al), we found higher PMP concentration in our healthy and obese Emirati 
population, with values of 30.2 and 53.2 nM of PMP, respectively. A similar pattern 
was also observed for nicotinamide, where our values in healthy and obese plasma 
samples (1206.5 and 3733.5 nM, respectively), were higher than the published average 
value of 274.4 nM. On the other hand, the average concentrations of the PLP, PN and 
PL were found to be lower in the plasma samples of both healthy and obese patients 
as compared with published concentrations. Hence, it appears that both healthy and 
obese Emirati plasma samples, as analyzed in the current study, showed high 
concentrations of PMP and nicotinamide and lower concentration than published 
values of PM, PLP, PN and PL vitamers. It is also worth noting that obese Emirati 
patients showed significantly higher average concentrations of PMP (p value = 0.002), 
PL (p value = 0.0006) and nicotinamide (p value < 0.0001) than healthy patients, as 
judged by student’s t-test analysis, Figure 25. Plasma concentrations of B6 vitamers 
PLP and PN were not significantly different between healthy and obese Emirati 
populations (Figure 25b and c). These interesting differences could be due to various 
factors, such as vitamin supplementation, higher caloric and food intake, other 
metabolic imbalances, single nucleotide polymorphisms or genetic differences. The 
exact nature and cause of this interesting finding will be carefully examined in future 
studies involving a larger population size. Nevertheless, this initial pilot study points 
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to the need and value of studying plasma concentrations of vitamers in metabolically 
distinct populations. 
 
                Table 16: Comparison between the concentrations of all analytes in the plasma 
                samples of healthy and obese Emirati population 
 
Analyte 
(nM) 
Healthy Plasma Obese Plasma 
Average Max Min Average Max Min 
PMP 30.2 82.3 10.9 53.2 243.9 12.0 
PLP 36.0 90.5 n.d. 38.0 69.3 n.d. 
PN 21.0 33.2 9.5 20.1 39.5 6.7 
PM Not detected 
PL 45.8 130.1 11.3 60.2 114.9 n.d. 
Nicotin-
amide 
1206.5 6005.1 275.2 3733.5 11303.4 372.3 
 
              Table 17: Comparison between the concentrations of all analytes in the  
              plasma samples of healthy population and those mentioned in the literature 
 
Analyte 
(nM) 
Healthy Emirati Plasma US Population [119] European Population  [159] 
Average Max Min Average Max  Min Average Max  Min 
PMP 30.2 82.3 10.9 4.9 7.6 2.1 Not detected 
PLP 36.0 90.5 n.d. 92.1 163.3 20.9 34.4 102.3 17.0 
PN 21.0 33.2 9.5 142.8 285.4 0.2 Not detected 
PM Not detected 4.1 7.7 0.4 Not detected 
PL 45.8 130.1 11.3 118.4 233.5 3.2 9.9 28.2 5.7 
Nicotin-
amide 
1206.5 6005.1 275.2 274.4 479.6 69.1 Not included 
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Figure 26:  Comparative analysis of various B6 vitamers and B3 (nicotinamide) in 
healthy versus obese Emirati population 
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              A comparative analysis was also carried out between the concentrations of 
the analytes found in the plasma samples of healthy and obese Emirati populations. 
Table 16 shows that PMP concentration in the obese Emirati population was 53.2 nM, 
which is higher than that in the plasma samples of healthy Emirati population; 30.2 
nM. The average concentration of PL (60.2 nM) and nicotinamide (3,733.5 nM) in 
obese population were both higher than their respective values detected in the healthy 
populations samples; 45.8 nM and 1,206.5 nM, respectively. It should be mentioned 
that PM was not detected in the plasma samples of both populations. It is also worth 
noting that obese Emirati population showed significantly higher average 
concentrations of PMP (p value = 0.002), PL (p value = 0.0006), and nicotinamide (p 
value < 0.0001) than healthy population, as judged by student t-test analysis. This is 
shown in Figure 26. Plasma concentration of B6 vitamers; PLP and PN were not 
significantly different between healthy and obese Emirati population (Figure 26b and 
c). Since synthetic vitamins were used to fortify food and as supplements in the late 
1930s, vitamin intake has significantly increased. The vitamin paradox in obesity may 
be a reflection of excess vitamin intake rather than vitamin deficiency given that there 
is a correlation between high vitamin intake and increased obesity [160]. These 
interesting differences could be related to various factors, such as vitamin 
supplementation, higher caloric and food intake, other metabolic imbalance, and single 
nucleotide polymorphisms or genetic differences. The exact nature and cause of these 
findings will be carefully examined in future studies involving a larger population size. 
Additionally, this data could also be correlated with gender, body weight, as well as 
other plasma parameters, such as complete blood count, HbA1c, interleukins, liver 
function enzymes, etc. Nevertheless, this initial pilot study points to the need and value 
of studying plasma concentration of vitamers in metabolically distinct populations. 
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              We also compared our data of healthy population with two representative data 
sets of vitamin concentrations in healthy human plasma previously published by 
Redeuil et al. in 2015 [119], and Midttun et al. in 2005 [159]. Table 17 shows higher 
PMP concentration in our healthy Emirati population, with value of 30.2 nM. A similar 
pattern was also observed for nicotinamide, where our value in healthy plasma sample 
was 1206.5 nM. These values were higher than their respective concentrations in the 
samples of US population. On the other hand, the average concentration of PLP, PN, 
and PL were found to be lower in the plasma samples of our healthy population as 
compared with those in the US population. It should be mentioned that PLP and PL 
vitamers were only detected in the plasma samples of European healthy population. 
The data shown in Table 17 indicate that the concentration of PL vitamer in the 
European population samples were one forth that of our healthy Emirati population, 
whereas the concentration of PLP was similar in both cases. It is also important to 
mention that nicotinamide was not studied in the work of Midttun et al, which explains 
why it was not compared with our results for this vitamers.  
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Chapter 4: Conclusions 
             In summary, the results presented here summarize the development of a rapid, 
sensitive and robust LC-MS/MS based assay for the simultaneous quantification of six 
different vitamers in human plasma. The method involves a simple, single step 
precipitation-based extraction of vitamins from human plasma for subsequent analysis 
by MRM-based LC-MS/MS method. This technique was subsequently used to analyze 
plasma samples taken from 57 healthy and 57 obese Emirati patients from a local 
hospital. Our results show that B6 vitamers as well as nicotinamide concentrations in 
healthy Emirati population are significantly different than those published in literature 
for Western populations. Additionally, we observed significant differences in plasma 
vitamin B6 and B3 concentrations between healthy and obese Emirati samples. The 
reasons behind this interesting finding will be the focus of future studies. It will also 
be interesting to see if the increased levels of B6 vitamers and vitamin B3 are 
correlated with any physiological imbalances or disease states in obese patients. 
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